On ECHEMI
Home > Drugs > Shanghai Shyndec Pharmaceutical Co., Ltd.
Shanghai Shyndec Pharmaceutical Co., Ltd.
  • Founded in:

    1996-11-27
  • Country:

    China China
  • Address:

    No. 378, Jianlu Road, Pudong New Area, Shanghai
  • Tax NO.:

    91310000630459924R
  • Registered Funds:

    1,341,172,692 yuan
  • Website:

  • Email:

Related Drugs
Gliclazide Tablets
This product contains 80 mg of gliclazide.
Name Description Content CAS NO. Registered Holders
Gliclazide

The second-generation sulfonylurea hypoglycemic drugs selectively act on pancreatic islet cells, promote insulin secretion and increase insulin release after ingesting glucose, inhibit liver glucose production and output; reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy.

More

The second-generation sulfonylurea hypoglycemic drugs selectively act on pancreatic islet cells, promote insulin secretion and increase insulin release after ingesting glucose, inhibit liver glucose production and output; reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy.

80mg 21187-98-4 23
Naftopidil Tablets
(±)-1-[4-(2-methoxyphenyl)piperazinyl]-3-(1-naphthyloxy)-2-propanol
Name Description Content CAS NO. Registered Holders
Naftopidil dihydrochloride

A selective α1 receptor antagonist that can inhibit the rise in blood pressure caused by α1 receptors. It has a hypotensive effect on a variety of hypertensive animal models, with a long duration of hypotensive effect, and does not cause reflex tachycardia during hypotensive treatment. No obvious first-dose effect or drug resistance was observed after multiple oral administrations. It can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and has no significant effect on cardiac output. It can also relieve the sympathetic tension of the prostate and urethra caused by the excitement of the receptor through the α1 receptor blocking effect, reduce the intraurethral pressure, and improve symptoms such as urination disorders caused by benign prostatic hyperplasia.

More

A selective α1 receptor antagonist that can inhibit the rise in blood pressure caused by α1 receptors. It has a hypotensive effect on a variety of hypertensive animal models, with a long duration of hypotensive effect, and does not cause reflex tachycardia during hypotensive treatment. No obvious first-dose effect or drug resistance was observed after multiple oral administrations. It can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and has no significant effect on cardiac output. It can also relieve the sympathetic tension of the prostate and urethra caused by the excitement of the receptor through the α1 receptor blocking effect, reduce the intraurethral pressure, and improve symptoms such as urination disorders caused by benign prostatic hyperplasia.

57149-07-2 13
Azithromycin dry suspension
Azithromycin
Name Description Content CAS NO. Registered Holders
Azithromycin

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. The mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of the bacterial ribosome and inhibiting RNA-dependent protein synthesis.

More

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. The mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of the bacterial ribosome and inhibiting RNA-dependent protein synthesis.

83905-01-5 39
Rhamnosus bismuth magnesium tablets
Each tablet of this product contains 300 mg of bismuth subnitrate, 200 mg of sodium bicarbonate, 400 mg of magnesium carbonate, and 25 mg of Salvia salviae scabra.
Name Description Content CAS NO. Registered Holders
Bismuth subnitrate

Dispersed microparticles can firmly adhere to the gastric and duodenal mucosa, forming a protective film and promoting mucosal regeneration.

More

Dispersed microparticles can firmly adhere to the gastric and duodenal mucosa, forming a protective film and promoting mucosal regeneration.

300mg 1304-85-4 17
Sodium bicarbonate

It is an antacid together with magnesium carbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid.

More

It is an antacid together with magnesium carbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid.

200mg 144-55-8 44
Magnesium carbonate

It is an antacid together with sodium bicarbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid.

More

It is an antacid together with sodium bicarbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid.

400mg 546-93-0 12
CORTEX FRANGULAE

It is a laxative and can combat constipation caused by bismuth nitrate.

More

It is a laxative and can combat constipation caused by bismuth nitrate.

25mg 0
Enalapril Maleate Tablets (10mg*8 tablets)
The main ingredient of this product is: Enalapril Maleate.
Name Description Content CAS NO. Registered Holders
Enalapril maleate

This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension.

More

This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension.

76095-16-4 35
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.